Kezar Life Sciences to Present at 36th Annual J.P. Morgan Health

Kezar Life Sciences to Present at 36th Annual J.P. Morgan Healthcare Conference

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE Kezar Life Sciences

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2018 /PRNewswire/ -- Kezar Life Sciences, a private, clinical-stage biopharmaceutical company developing novel small molecule therapeutics, today announced that John Fowler, Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 10:00 AM PT in San Francisco, CA.

Kezar Life Sciences Logo (PRNewsfoto/Kezar Life Sciences)

About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is a privately-held, clinical stage company developing novel small molecule therapeutics to treat autoimmune disorders and malignant diseases. Kezar's lead drug candidate, KZR-616, leverages more than a decade of research directed by co-founder Christopher Kirk into the unique role of the immunoproteasome in immune cell biology. In addition, Kezar is pursuing drug discovery programs targeting protein secretion and transmembrane protein expression that include a structured research collaboration with UC San Francisco. Kezar Life Sciences is backed by leading life sciences investors, including Cormorant Asset Management, Morningside Venture, Cowen Health Care Investments, EcoR1 Capital, Omega Funds, Pappas Capital, Qiming Venture Partners, Bay City Capital, and others. For more information, please visit


For investors:  

Alex Gray, Burns McClellan, Inc., on behalf of Kezar Life Sciences



Michael Wolfe, Director of Finance & Operations at Kezar Life Sciences


Cision View original content with multimedia:

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly